Literature DB >> 24840933

[Importance of PET for surgery of recurrent thyroid cancer].

C Haane1, M Colombo-Benkmann.   

Abstract

BACKGROUND: The early detection of recurrent thyroid cancer and focussed surgery are essential for patients' prognosis. Using I-131 whole body scintigraphy is often not sufficient to detect recurrent carcinoma making other imaging methods necessary to identify the tumor. Recent studies showed that positron emission tomography-computed tomography (PET/CT) is able to identify recurrent carcinoma and metastasis at an early stage.
OBJECTIVE: The aim of this study was an evaluation of the impact of PET/CT on diagnostic and operation strategies in recurrent thyroid cancer.
METHODS: A review of the literature was carried out combined with a case report from the daily practice. Furthermore, flow charts were created to clarify the aftercare procedure.
RESULTS: In patients with recurrent thyroid cancer PET/CT significantly increased the identification of recurrent tumors and metastases. Depending on the subtype of cancer, different tracers are used. The use of a metabolically active tracer which shows the increase of tumor metabolism and the morphological correlation of the tumor using a CT scan enable preoperative planning for a focussed surgical approach.
CONCLUSIONS: The PET/CT procedure should be an integral part of the aftercare procedure in thyroid cancer for early identification of recurrent tumors and to enable focussed surgery.

Entities:  

Mesh:

Year:  2014        PMID: 24840933     DOI: 10.1007/s00104-013-2667-9

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  20 in total

Review 1.  PET/CT imaging of thyroid cancer.

Authors:  Camila Mosci; Andrei Iagaru
Journal:  Clin Nucl Med       Date:  2011-12       Impact factor: 7.794

2.  Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-11       Impact factor: 3.352

3.  Analysis of prognostic factors in patients with multiple recurrences of papillary thyroid carcinoma.

Authors:  Kwang-Min Kim; Joon-Beom Park; Keum-Seok Bae; Seong-Joon Kang
Journal:  Surg Oncol       Date:  2011-08-19       Impact factor: 3.279

4.  Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma.

Authors:  P Gasparoni; D Rubello; G Ferlin
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

5.  Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.

Authors:  B Beuthien-Baumann; A Strumpf; J Zessin; J Bredow; J Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-14       Impact factor: 9.236

Review 6.  ¹⁸F-FDG-PET and ¹⁸F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis.

Authors:  Xu Cheng; Lihua Bao; Zhaoqiang Xu; Dianfu Li; Jie Wang; Yongjun Li
Journal:  J Med Imaging Radiat Oncol       Date:  2012-03-06       Impact factor: 1.735

7.  Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study.

Authors:  T J Musholt; P B Musholt; F Dehdashti; J F Moley
Journal:  Surgery       Date:  1997-12       Impact factor: 3.982

8.  Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?

Authors:  Pierre Vera; Caroline Kuhn-Lansoy; Agathe Edet-Sanson; Sebastien Hapdey; Romain Modzelewski; Anne Hitzel; Joelle d'Anjou; Jean-Pierre Basuyau
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

9.  [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)].

Authors:  M Dietlein; J Dressler; W Eschner; F Grünwald; M Lassmann; B Leisner; M Luster; E Moser; Chr Reiners; H Schicha; O Schober
Journal:  Nuklearmedizin       Date:  2007       Impact factor: 1.379

10.  The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview.

Authors:  Giorgio Treglia; Salvatore Annunziata; Barbara Muoio; Massimo Salvatori; Luca Ceriani; Luca Giovanella
Journal:  Int J Endocrinol       Date:  2013-04-09       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.